BioCentury
ARTICLE | Clinical News

OTO-104: Phase II data

August 22, 2016 7:00 AM UTC

A U.K. Phase II trial in 128 patients with unilateral Meniere’s disease showed that intratympanic injections of 12 mg OTO-104 every 3 months for 1 year were well tolerated. Otonomy said there were no ...